# GPT-5.2 Review

**Role:** External referee review
**Model:** openai/gpt-5.2
**Paper:** paper.pdf
**Timestamp:** 2026-02-20T10:46:41.375098
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 14965 in / 5111 out
**Response SHA256:** 22c4b61d0d66d388

---

## Referee Report: “Paying for Pixels: The Null Effect of Telehealth Payment Parity on Medicaid Behavioral Health Provider Supply”

### Summary
This paper studies whether permanent Medicaid telehealth **payment parity** laws (26 states, 2020–2023) increased Medicaid behavioral health provider participation, using T‑MSIS “universe” claims data (2018–2024). The headline result is a **precisely estimated null** for provider counts and other volume/spending outcomes, using **Callaway & Sant’Anna (2021)** DiD with never-treated controls, complemented by Sun–Abraham and TWFE.

The question is important, the dataset is potentially definitive for this margin, and the authors largely use modern DiD tools appropriately. The main weaknesses are (i) clarifying *what exactly is identified* given pandemic-era nationwide waivers and the inability to observe telehealth modality, (ii) better treatment measurement and policy heterogeneity (scope/enforcement/MCO rules), (iii) more transparent uncertainty reporting (CIs throughout) and sensitivity to small number of clusters / aggregation choices, and (iv) deeper engagement with Medicaid managed care / reimbursement implementation details that may rationalize the null.

Below I provide detailed, constructive comments aimed at making the paper publishable in a top general-interest or AEJ:EP field.

---

# 1. FORMAT CHECK

### Length
- Appears to be **~30–40 pages of main text** in rendered form (hard to be exact from LaTeX source), plus appendices. This likely **meets** the “25 pages excluding references/appendix” expectation.

### References / bibliography coverage
- The paper cites key DiD methodology papers (Callaway–Sant’Anna; Sun–Abraham; Goodman-Bacon; Roth) and some domain references.
- However, the telehealth and Medicaid policy literatures are **not yet fully covered** (details and missing references below in Section 4).

### Prose and structure
- Major sections (Introduction, Background, Strategy, Results, Discussion) are in **paragraph form**, not bullets. Good.
- Appendix uses bullets appropriately for code lists.

### Section depth (3+ substantive paragraphs)
- Introduction, Institutional Background, Empirical Strategy, Results, Discussion all have multiple substantive paragraphs. Good.
- The **Conceptual Framework** is concise but still adequate (could be strengthened with one additional paragraph translating the model into empirically testable margins given data constraints).

### Figures
- The LaTeX includes `\includegraphics{...}` for figures; as requested, I do **not** judge rendering quality here. In the final PDF, ensure:
  - axes labeled, units/time period clear,
  - event-study figures show confidence bands and reference lines,
  - adoption timeline includes counts and cohort definitions.

### Tables
- Tables contain real numbers and clustered SEs. Good.
- Recommendation: add explicit **95% confidence intervals** in main tables (or in notes) and make the N and clustering level extremely explicit throughout.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

Overall, the paper is close to passing a “top-journal inference” bar, but several items should be tightened.

## (a) Standard errors on every coefficient
- **PASS** for the displayed regression tables (e.g., TWFE table reports SEs in parentheses; CS ATT table reports SEs).
- For Sun–Abraham results and DDD results: these are discussed in text; ensure **all corresponding coefficients are shown in a table** with SEs, not only described narratively.

## (b) Significance testing
- **PASS**: standard errors and significance are discussed.
- However, relying on “no coefficient reaches p<0.10” is not ideal for a null-results paper. The paper should foreground **estimation + uncertainty** rather than “non-significance.”

## (c) Confidence intervals (95%)
- **PARTIAL FAIL (fixable)**: the text mentions 95% CIs and “rules out ±10%,” but the main tables generally do not display **95% CIs** directly.
  - For a null-results contribution, I strongly recommend adding 95% CIs **in the main result table** (e.g., `ATT`, `SE`, `95% CI`, `percent effect CI`) and in the TWFE table notes.

## (d) Sample sizes (N) for all regressions
- **PASS** in TWFE table: Observations = 1,428 (51×28).
- CS table does not state N directly (though design implies it). Add N and number of treated/control units in that table too for completeness (even if redundant).

## (e) DiD with staggered adoption
- **PASS**: uses Callaway–Sant’Anna with never-treated controls; also discusses Sun–Abraham and Goodman-Bacon.
- One concern: you note pre-trend joint test is “unavailable due to singular covariance matrix.” This will bother many readers. You should:
  1. Report an alternative joint pre-trends assessment (e.g., fewer pre-period bins; or use the Sun–Abraham event-study with aggregated leads; or randomization inference / Fisher-style pretrend tests).
  2. Be explicit about what leads are identified for late adopters and how that affects variance estimation.

## (f) RDD
- Not applicable.

## Additional inference issues to address
1. **Bootstrap + clustering with 51 units**: 51 clusters is usually okay, but for policy adoption at the state level, reviewers often ask for:
   - **wild cluster bootstrap** p-values (Cameron, Gelbach & Miller style) for key estimates, and/or
   - randomization inference using adoption timing (especially given the “19 states in 2021” bunching).
2. **Simultaneous bands**: You mention simultaneous bands in event studies—good. Clarify the method (e.g., multiplier bootstrap, Bonferroni, or uniform confidence bands from `did`).

---

# 3. IDENTIFICATION STRATEGY

### Credibility
The core identification is plausible and the authors take modern DiD concerns seriously. Still, the paper’s biggest vulnerability is that **the treatment may not generate a meaningful change in incentives** relative to the COVID-era baseline, and that **implementation is mediated by managed care**.

Key identification concerns and how to address them:

## 3.1 What exactly changes at “permanent parity” adoption?
A sophisticated reader will ask: during 2020–2021, nearly all states had emergency telehealth expansions and often de facto parity. If so, your treatment is not “telehealth becomes financially viable,” but “the state codifies parity permanently.”

- You partially address this with a post‑2022 subsample and a Georgia discussion, but it needs to be **central**:
  - Provide a **timeline figure/table** that distinguishes: (i) emergency telehealth authorization, (ii) emergency payment rules (if known), (iii) permanent parity effective date.
  - Clarify whether permanent parity was binding relative to the emergency regime in each state.

## 3.2 Treatment heterogeneity and misclassification
Parity laws differ (video-only vs audio-only; scope across services; whether they bind Medicaid FFS vs MCO contracts; whether they apply to behavioral health specifically). If your treatment indicator ignores scope, you risk attenuation toward zero.

- Strong suggestion: code **treatment intensity**:
  - parity includes audio-only (yes/no),
  - parity applies explicitly to Medicaid MCOs (yes/no),
  - parity applies to behavioral health services specifically or all outpatient services,
  - enforcement mechanism/implementation guidance existence (yes/no).
- Then estimate heterogeneous effects by these dimensions (even if noisy) and present as a key extension. A credible “null” paper should show it is not just “average of apples and oranges.”

## 3.3 Outcome measurement and the “provider supply” construct
You measure supply as “unique billing NPIs in state-quarter for H-codes.” That’s reasonable, but several measurement choices need more stress-testing:

1. **CMS suppression of cells with <12 claims**: this can mechanically affect “unique billing NPIs,” especially for low-volume/rural providers.
   - If parity plausibly induces *small-volume entrants*, suppression may make them invisible, biasing toward null.
   - At minimum: show sensitivity using outcomes less sensitive to suppression (e.g., paid amounts, claims) and/or show that suppressed share is stable and small by state over time. If possible, quantify how many provider-months are lost due to suppression and whether it changes around adoption.

2. **Assigning providers to states via NPPES primary practice state**:
   - For telehealth, providers could bill in a state while residing elsewhere (though Medicaid enrollment is state-specific). Still, NPPES location may not reflect billing state perfectly.
   - You should validate: compare NPPES state to billing state if T‑MSIS contains state identifiers; or show robustness restricting to organizational NPIs likely located in-state.

3. **Organizational vs individual NPIs**:
   - Entry may occur at the organization level (community mental health centers) rather than clinician NPI.
   - Split the outcome: unique organizational NPIs vs unique individual NPIs; effects could offset.

## 3.4 Placebo/DDD validity
The personal care placebo is a nice idea, but the identifying assumption for DDD is that parity does not differentially affect the *gap* between BH and personal care in treated states absent the law.

- Potential issue: personal care markets were heavily affected by COVID labor shortages, wage policies, and HCBS expansions—possibly in ways correlated with telehealth policy environments.
- Strengthen by:
  - Adding a second placebo category less entangled with HCBS labor markets (if feasible): e.g., dental codes or some other Medicaid service plausibly not telehealth-deliverable and not undergoing contemporaneous workforce crises.
  - Showing pre-trend event studies for the **BH–PC gap** directly.

## 3.5 Robustness and falsification
You already do: event-study pretrends, leave-one-out, post-COVID subsample, Bacon decomposition. Good.

Additional checks I recommend:
- **Negative control timing**: assign “fake adoption dates” to never-treated states (randomly or matched on covariates) and show the distribution of placebo ATTs.
- **Border spillovers**: if any parity states border non-parity states, you might look for changes in border-county provider counts (if geography exists). Even a coarse version could be informative.
- **Policy bundling**: control for other state behavioral health initiatives (e.g., 988 implementation timing; Medicaid rate increases; licensure compacts). Even if you cannot comprehensively measure them, discuss them more systematically.

---

# 4. LITERATURE (MISSING REFERENCES + BibTeX)

The current literature review is a good start, but it needs (i) more foundational telehealth parity policy work, (ii) Medicaid telehealth/behavioral health specific evidence, (iii) managed care implementation and provider participation.

Below are specific additions with BibTeX. (Some of your current citations like `jonathan2023` and `baker2025` are unclear/possibly placeholders; ensure they correspond to citable working papers with stable links.)

## 4.1 Key DiD / event-study references (add if not already properly cited)
You cite most, but I would ensure these are included and correctly referenced:

```bibtex
@article{DeChaisemartinDHaultfoeuille2020,
  author = {de Chaisemartin, Cl{\'e}ment and D'Haultfoeuille, Xavier},
  title = {Two-Way Fixed Effects Estimators with Heterogeneous Treatment Effects},
  journal = {American Economic Review},
  year = {2020},
  volume = {110},
  number = {9},
  pages = {2964--2996}
}
```

```bibtex
@article{GoodmanBacon2021,
  author = {Goodman-Bacon, Andrew},
  title = {Difference-in-Differences with Variation in Treatment Timing},
  journal = {Journal of Econometrics},
  year = {2021},
  volume = {225},
  number = {2},
  pages = {254--277}
}
```

```bibtex
@article{CallawaySantAnna2021,
  author = {Callaway, Brantly and Sant'Anna, Pedro H. C.},
  title = {Difference-in-Differences with Multiple Time Periods},
  journal = {Journal of Econometrics},
  year = {2021},
  volume = {225},
  number = {2},
  pages = {200--230}
}
```

```bibtex
@article{SunAbraham2021,
  author = {Sun, Liyang and Abraham, Sarah},
  title = {Estimating Dynamic Treatment Effects in Event Studies with Heterogeneous Treatment Effects},
  journal = {Journal of Econometrics},
  year = {2021},
  volume = {225},
  number = {2},
  pages = {175--199}
}
```

## 4.2 Telehealth policy and parity (important for positioning)
You cite some telehealth work, but top journals will expect a broader grounding in telehealth adoption/utilization and payment incentives:

```bibtex
@article{MehrotraRay2020,
  author = {Mehrotra, Ateev and Ray, Kedar and Brockmeyer, David M. and Barnett, Michael L. and Bender, Jeffrey A.},
  title = {Rapidly Converting to ``Virtual Practices'': Outpatient Care in the Era of Covid-19},
  journal = {NEJM Catalyst Innovations in Care Delivery},
  year = {2020},
  volume = {1},
  number = {2},
  pages = {1--11}
}
```

```bibtex
@article{BestsennyyGilbertHarrisRost2021,
  author = {Bestsennyy, Oleg and Gilbert, Greg and Harris, Alex and Rost, Jennifer},
  title = {Telehealth: A Quarter-Trillion-Dollar Post-COVID-19 Reality?},
  journal = {McKinsey \& Company Report},
  year = {2021},
  volume = { },
  pages = { }
}
```
*(If you prefer peer-reviewed only, swap this for a JAMA Health Forum / Health Affairs telehealth synthesis; the point is to cite a canonical piece on post-COVID telehealth scale.)*

A particularly relevant Health Affairs strand (often cited in policy evaluation) is:
```bibtex
@article{UscherPacia2021,
  author = {Uscher-Pines, Lori and Sousa, Jill and Raja, Pooja and Mehrotra, Ateev and Barnett, Michael and Huskamp, Haiden A.},
  title = {Sudden Rise in Virtual Mental Health and Substance Use Visits During COVID-19: Implications for Telehealth Policy},
  journal = {Health Affairs},
  year = {2021},
  volume = {40},
  number = {10},
  pages = {1635--1642}
}
```

## 4.3 Medicaid provider participation and reimbursement (beyond the ACA fee bump)
You cite Decker and Candon/Alexander; also consider anchoring participation elasticity and Medicaid “rate adequacy” debates:

```bibtex
@article{KaiserFamilyFoundation2019MedicaidPhysicianFees,
  author = {{Kaiser Family Foundation}},
  title = {Medicaid Physician Fees Compared to Medicare Fees in 2019},
  journal = {KFF Issue Brief},
  year = {2019},
  volume = {},
  pages = {}
}
```
*(Not a journal article, but widely cited. If the journal disfavors gray literature, keep it in an online appendix and rely on peer-reviewed sources where possible.)*

Also consider Medicaid managed care’s role in provider networks and reimbursement implementation:
```bibtex
@article{SommersGawandeBaicker2017,
  author = {Sommers, Benjamin D. and Gawande, Atul A. and Baicker, Katherine},
  title = {Health Insurance Coverage and Health --- What the Recent Evidence Tells Us},
  journal = {New England Journal of Medicine},
  year = {2017},
  volume = {377},
  number = {6},
  pages = {586--593}
}
```
*(This is broader, but can help motivate Medicaid institutional constraints; if you have a more direct Medicaid managed care reimbursement enforcement cite, that may be preferable.)*

## 4.4 Null results / publication bias
You cite Franco et al. and Abadie; add the classic publication bias reference:
```bibtex
@article{Dickersin1990,
  author = {Dickersin, Kay},
  title = {The Existence of Publication Bias and Risk Factors for Its Occurrence},
  journal = {JAMA},
  year = {1990},
  volume = {263},
  number = {10},
  pages = {1385--1389}
}
```

---

# 5. WRITING QUALITY (CRITICAL)

### Prose vs bullets
- **PASS**: main sections are well written in paragraphs.

### Narrative flow
- The introduction is strong and readable. The paper does a good job stating the question, policy context, and main results quickly.
- One improvement: the introduction currently emphasizes “this dataset is universe and high power,” but for a general-interest journal you need an even clearer statement of **why the extensive margin should have moved** under parity and why it matters if it didn’t.

### Accessibility
- Generally accessible. Econometric choices are explained with reasonable intuition.
- Still, a non-specialist may struggle with:
  - why TWFE differs from CS (you explain it, but you could simplify further),
  - what H-codes capture (you do list examples—good),
  - why “providers” means billing NPIs and what that implies about “supply.”

### Tables
- Tables are clear; add:
  - explicit **95% CI** columns,
  - explicit clustering level and bootstrap method in each relevant table,
  - for each outcome, consider including the **control mean** (pre-period or overall) so magnitudes are interpretable.

---

# 6. CONSTRUCTIVE SUGGESTIONS (HOW TO MAKE THIS MORE IMPACTFUL)

A null paper becomes top-journal publishable when it (i) convinces readers the policy really was a policy shock, (ii) rules out meaningful effects on the intended margin, and (iii) teaches something general about constraints/mechanisms. Here are concrete ways to get there:

## 6.1 Strengthen treatment measurement and “first stage”
Even without telehealth modifiers, you can often build a “first stage” proxy:

- If any subset of claims includes telehealth modifiers/place-of-service (even for a subset of states/years), use it to show parity increased telehealth billing *where measurable*.
- Alternatively, use external telehealth utilization measures (e.g., CDC/NCHS, FAIR Health, CMS telehealth reports) at the state level to show that parity adoption correlates with telehealth intensity—otherwise readers will suspect “no shock.”

## 6.2 Distinguish extensive margin vs compositional changes
Because you cannot see modality, the cleanest way to add value is to show **other margins consistent with entry**:
- entry should increase providers particularly in **underserved/rural** settings → if you can classify providers by rurality using NPPES ZIP → RUCA mapping, test heterogeneous effects by rurality.
- entry might show up in **new NPIs** (NPI issuance date): do parity laws increase the number of NPIs newly billing Medicaid behavioral health (within-state)?
- entry might show up in **out-of-state NPIs** enrolling (if measurable via NPPES state vs billing state).

## 6.3 Medicaid managed care implementation
A large share of Medicaid behavioral health is paid via MCOs/ASOs/MBHOs. Payment parity statutes may not translate into actual paid rates if:
- MCO contracts lag,
- provider contracts are not renegotiated,
- parity applies only to FFS schedule.

Actionable addition:
- stratify states by Medicaid delivery system (high MCO penetration vs FFS) and test heterogeneity.
- add an institutional appendix describing how parity interacts with MCO rate setting in Medicaid (even descriptive, with citations).

## 6.4 Address “suppression <12 claims” more directly
This is a serious measurement concern for the provider-count outcome.
- Show a plot/table of the fraction of provider-month records suppressed (or dropped) by state over time if possible.
- Provide a bound/sensitivity argument: even if X suppressed providers entered, what effect size could be hidden?

## 6.5 Improve pre-trend testing presentation
Because you cannot compute a joint test due to singular covariance, do one of:
- bin leads into two pre-period bins (e.g., −8 to −5, −4 to −1) and test,
- use Sun–Abraham with fewer leads,
- use randomization inference on pre-period coefficients.

## 6.6 Clarify estimand and weighting
Callaway–Sant’Anna can deliver different aggregates (simple average, group-size weighted, etc.).
- State explicitly: are you estimating ATT averaged across groups weighted by group size? by state? by outcome variance?
- For policy, a **state-weighted** estimand might be most intuitive; a **beneficiary-weighted** estimand might be more relevant for access. Consider reporting both.

---

# 7. OVERALL ASSESSMENT

### Key strengths
- Important policy question with clear welfare relevance (behavioral health access and Medicaid).
- Excellent data scale (T‑MSIS) and credible state-by-time policy variation.
- Uses modern staggered DiD estimators appropriately; includes meaningful robustness (placebos, event studies, leave-one-out, Bacon decomposition).
- The paper is readable and has a clear bottom line.

### Critical weaknesses (fixable but substantive)
1. **Treatment is plausibly non-binding** relative to COVID-era policies and MCO implementation; the paper needs stronger evidence that “permanent parity” altered reimbursement incentives.
2. **Provider-supply measurement** may be biased toward null due to CMS suppression and NPPES-based state assignment; needs sensitivity.
3. **Uncertainty reporting** should be upgraded for a null-results paper: show **95% CIs everywhere**, consider wild bootstrap/randomization inference, and clarify event-study band construction.
4. **Literature positioning** needs deeper engagement with Medicaid managed care/payment implementation and telehealth parity evidence.

### Concrete revision priorities
- Add a main results table with ATT + SE + **95% CI** + implied % effect CI + N.
- Add treatment heterogeneity/intensity coding and subgroup estimates.
- Add at least one credible “first-stage” or proxy for telehealth modality change (or a more forceful argument why it’s unnecessary and what is still identified).
- Address suppression and provider-state assignment sensitivity.

---

DECISION: MAJOR REVISION